300 多名生殖健康研究人员的法庭之友意见书支持米非司酮的安全性和有效性。
Amicus brief of over 300 reproductive health researchers supports mifepristone's safety and effectiveness.
作者信息
Barrow Amanda, Cohen Cathren, Serpico Jaclyn, Goodman Melissa, Grossman Daniel, Raifman Sarah, Upadhyay Ushma
机构信息
Center on Reproductive Health, Law, and Policy, University of California Los Angeles, Los Angeles, California, USA.
Department of Obstetrics, Gynecology, & Reproductive Sciences, University of California San Francisco, Advancing New Standards in Reproductive Health, Oakland, California, USA.
出版信息
Perspect Sex Reprod Health. 2024 Dec;56(4):317-319. doi: 10.1111/psrh.12282. Epub 2024 Jul 29.
On January 30, 2024, over 300 researchers filed an amicus brief in FDA v. Alliance for Hippocratic Medicine, a United States (US) Supreme Court case concerning the regulatory status of mifepristone, one of two drugs used in medication abortion. In this Comment we summarize the legal challenge, responses from the FDA and drug manufacturer to these challenges, oral arguments presented before the Court, and the implications of the Court's decision on access to mifepristone in the US. We also summarize the content of the accompanying amicus brief.
2024年1月30日，300多名研究人员在美国最高法院审理的“美国食品药品监督管理局诉希波克拉底医学联盟案”（FDA v. Alliance for Hippocratic Medicine）中提交了一份法庭之友意见书。该案件涉及药物流产中使用的两种药物之一米非司酮的监管地位。在本评论中，我们总结了法律挑战、美国食品药品监督管理局（FDA）和药品制造商对这些挑战的回应、在法庭上进行的口头辩论，以及法院裁决对美国米非司酮获取情况的影响。我们还总结了所附法庭之友意见书的内容。
Zotero 插件